Search

Displaying results 9691 - 9700 of 10000 in total
  1. Drug

    Modakafusp alfa

    go.drugbank.com/drugs/DB16399
    Investigational

    Modakafusp alfa is under investigation in clinical trial NCT03215030 (A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory

  2. Drug

    Feladilimab

    go.drugbank.com/drugs/DB16415
    Investigational

    Feladilimab is under investigation in clinical trial NCT04128696 (Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell

  3. Drug

    Sonelokimab

    go.drugbank.com/drugs/DB18843
    Investigational

    Sonelokimab is under investigation in clinical trial NCT06411379 (Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe

    Synonyms: M-1095 (anti-interleukin (il)-17a/f single-domain antibody)
  4. Drug

    Suvecaltamide

    go.drugbank.com/drugs/DB19139
    Investigational

    Suvecaltamide is under investigation in clinical trial NCT05122650 (A Study to Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)).

    Synonyms: 4-(1-methylethyl)-n-((1r)-1-(5-(2,2,2-trifluoroethoxy)-2-pyridinyl)ethyl)benzeneacetamide, Benzeneacetamide, 4-(1-methylethyl)-n-((1r)-1-(5-(2,2,2-trifluoroethoxy)-2-pyridinyl)ethyl)-
  5. Drug

    BN‐Brachyury vaccine

    go.drugbank.com/drugs/DB17425
    Experimental

    BN‐Brachyury vaccine is a novel prime‐boost therapeutic cancer immunotherapy. It is composed of the [MVA-BN-brachyury-TRICOM vaccine] and the fowlpox virus(FPV)‐Brachyury booster vaccine.[A255173]

    Synonyms: BN‐Brachyury vaccine
  6. Drug

    NP-G2-044

    go.drugbank.com/drugs/DB14995
    Investigational

    NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-Ring
  7. Drug

    Lintuzumab satetraxetan AC-225

    go.drugbank.com/drugs/DB15053
    Investigational

    Lintuzumab actinium Ac-225 is under investigation in clinical trial NCT00672165 (Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced

    International brands: Actimab-A
  8. Drug

    MEDI-6469

    go.drugbank.com/drugs/DB15306
    Investigational

    MEDI-6469 is a monoclonal antibody under investigation in clinical trial NCT02205333 (A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies

  9. Drug

    AGG-523

    go.drugbank.com/drugs/DB15460
    Investigational

    AGG-523 is under investigation in clinical trial NCT00380900 (Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy subjects and in subjects

  10. Drug

    Renvistobart

    go.drugbank.com/drugs/DB19065
    Investigational

    Renvistobart is under investigation in clinical trial NCT02913313 (A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors).